Tenaya Therapeutics Stock In The News

TNYA Stock  USD 2.38  0.22  10.19%   
Our overall analysis of Tenaya Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Tenaya Therapeutics. The specific impact of Tenaya Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Tenaya Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Tenaya Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Tenaya Therapeutics Backtesting and Tenaya Therapeutics Hype Analysis.
For information on how to trade Tenaya Stock refer to our How to Trade Tenaya Stock guide.

Tenaya Therapeutics Today Top News and Investor Outlook

Yahoo News
20 Countries with the Highest Heart Disease Deaths Per Capita
https://finance.yahoo.com/news/20-countries-highest-heart-disease-111929595.html
 Bullish
Yahoo News
14 Stocks With Heavy Insider Buying In 2024
https://finance.yahoo.com/news/14-stocks-heavy-insider-buying-080208688.html
 Bullish
Macroaxis News: globenewswire.com
Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference
https://www.globenewswire.com/news-release/2023/11/21/2784439/0/en/Tenaya-Therapeutics-to-Participate-at-the-35th-Annual-Piper-Sandler-Healthcare-Conference.html
 Bullish
Macroaxis News: globenewswire.com
Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
https://www.globenewswire.com/news-release/2023/11/08/2776711/0/en/Tenaya-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html
 Neutral
Macroaxis News: globenewswire.com
Tenaya Therapeutics Announces FDA Cleara...
https://www.globenewswire.com/news-release/2023/10/26/2767510/0/en/Tenaya-Therapeutics-Announces-FDA-Clearance-to-Begin-Clinical-Testing-of-TN-401-Gene-Therapy-for-the-Treatment-of-PKP2-Associated-Arrhythmogenic-Right-Ventricular-Cardiomyopathy.html
 Neutral
Macroaxis News: globenewswire.com
Tenaya Therapeutics Presents Encouraging...
https://www.globenewswire.com/news-release/2023/10/09/2756679/0/en/Tenaya-Therapeutics-Presents-Encouraging-New-Clinical-and-Preclinical-Data-from-HDAC6-Inhibitor-Program-TN-301-for-the-Potential-Treatment-of-Heart-Failure-with-Preserved-Ejection-.html
 Bullish
Macroaxis News: globenewswire.com
Tenaya Therapeutics Doses First Patient ...
https://www.globenewswire.com/news-release/2023/10/05/2755400/0/en/Tenaya-Therapeutics-Doses-First-Patient-in-the-MyPeak-1-Phase-1b-Clinical-Trial-of-TN-201-for-the-Treatment-of-MYBPC3-Associated-Hypertrophic-Cardiomyopathy.html
 Bullish
Macroaxis News: globenewswire.com
Tenaya Therapeutics Publishes Preclinica...
https://www.globenewswire.com/news-release/2023/10/02/2753212/0/en/Tenaya-Therapeutics-Publishes-Preclinical-Data-in-Circulation-Highlighting-the-Clinical-Potential-of-Cellular-Reprogramming-for-Cardiac-Regeneration.html
 Bullish
Macroaxis News: globenewswire.com
Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences
https://www.globenewswire.com/news-release/2023/09/21/2747656/0/en/Tenaya-Therapeutics-to-Present-Data-for-TN-301-and-TN-201-at-Upcoming-Medical-Conferences.html
 Bullish
Macroaxis News: globenewswire.com
Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference
https://www.globenewswire.com/news-release/2023/08/31/2735693/0/en/Tenaya-Therapeutics-to-Participate-at-the-21st-Annual-Morgan-Stanley-Global-Healthcare-Conference.html
 Bullish

Tenaya Therapeutics Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Tenaya and other traded companies coverage with news coverage. We help investors stay connected with Tenaya headlines for the 22nd of November to make an informed investment decision based on correlating the impacts of news items on Tenaya Stock performance. Please note that trading solely based on the Tenaya Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Tenaya Therapeutics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Tenaya Therapeutics investors visualize upcoming and past events in order to time the market based on Tenaya Therapeutics noise-free hype analysis.
Tenaya Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Tenaya earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Tenaya Therapeutics that are available to investors today. That information is available publicly through Tenaya media outlets and privately through word of mouth or via Tenaya internal channels. However, regardless of the origin, that massive amount of Tenaya data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Tenaya Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Tenaya Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Tenaya Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Tenaya Therapeutics alpha.

Tenaya Largest EPS Surprises

Earnings surprises can significantly impact Tenaya Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-08-09
2024-06-30-0.39-0.340.0512 
2023-08-09
2023-06-30-0.5-0.450.0510 
2024-11-07
2024-09-30-0.3671-0.30.067118 
2023-11-08
2023-09-30-0.47-0.390.0817 
2022-11-10
2022-09-30-0.64-0.74-0.115 
2022-05-11
2022-03-31-0.64-0.75-0.1117 
View All Earnings Estimates

Tenaya Therapeutics Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Tenaya Therapeutics Stock. Current markets are strongly bullish. About 82% of major world exchanges and indexes are currently up. See today's market update for more information.
Gurufocus Stories at Macroaxis
19th of November 2024
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635
at gurufocus.com 
Gurufocus Stories at Macroaxis
15th of November 2024
RA Capital Managements Strategic Acquisition in Tenaya Therapeutics
at gurufocus.com 
seekingalpha News
7th of November 2024
Tenaya Therapeutics GAAP EPS of -0.30
at seekingalpha.com 
Macroaxis News
18th of October 2024
Acquisition by Burroughs Amy L. of 34000 shares of Tenaya Therapeutics at 2.04 subject to ...
at MacroaxisInsider 
Macroaxis News
26th of September 2024
Acquisition by Column Group Iii Gp, Lp of 2222222 shares of Tenaya Therapeutics at 4.5 sub...
at MacroaxisInsider 
Google News at Macroaxis
16th of September 2024
Tenaya Therapeutics Announces Board Restructuring and New Equity Plan - TipRanks
at news.google.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Tenaya Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Tenaya Therapeutics' short interest history, or implied volatility extrapolated from Tenaya Therapeutics options trading.
When determining whether Tenaya Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tenaya Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tenaya Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tenaya Therapeutics Stock:
Check out Tenaya Therapeutics Backtesting and Tenaya Therapeutics Hype Analysis.
For information on how to trade Tenaya Stock refer to our How to Trade Tenaya Stock guide.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tenaya Therapeutics. If investors know Tenaya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tenaya Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.44)
Return On Assets
(0.46)
Return On Equity
(0.84)
The market value of Tenaya Therapeutics is measured differently than its book value, which is the value of Tenaya that is recorded on the company's balance sheet. Investors also form their own opinion of Tenaya Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Tenaya Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tenaya Therapeutics' market value can be influenced by many factors that don't directly affect Tenaya Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tenaya Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tenaya Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tenaya Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.